Spinal Metastases Clinical Trial
Official title:
A Phase II Randomized Trial of Combined Radiotherapy and Vertebroplasty to Improve the Quality of Life of Patients With Painful Metastatic Localized Spinal Lesions
Verified date | June 2024 |
Source | AHS Cancer Control Alberta |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Since patients with spinal metastases are living longer, durable palliation with long-term tumor control are becoming increasingly important. EBRT results in durable local control of bone metastasis. However, about 25 % of patients with spinal metastases only achieved complete pain relief following EBRT for a median duration of less than 4 months. This could be partly due to spinal instability. In addition, almost half of the patients who receive EBRT will subsequently develop VCFs . Hence, RT does not stabilize the spine secondary to VCFs and is not effective in preventing imminent VCFs. Vertebroplasty has rapidly reduced pain and improved function in patients with VCFs. However, vertebroplasty does not provide local tumor control similar to EBRT. It is theorized that combining vertebroplasty with EBRT will stabilize the spine, relieve the pain, prevent imminent VCFs and minimize or avoid the need for opioids. It is hypothesized that combining a spine stabilization procedure such as vertebroplasty with RT will be the most effective management for patients with spinal metastases than RT alone for patients with spinal metastases. Combined vertebroplasty and radiotherapy is not a standard treatment option at present. This study is designed to quantify the advantage of adding vertebroplasty to radiotherapy for patients with spinal metastases. If the study is proven to be significant, it could become the standard of care for patients with spinal metastases.
Status | Recruiting |
Enrollment | 64 |
Est. completion date | November 1, 2026 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Participants capable of giving informed consent, or if appropriate, participants having an acceptable individual capable of giving consent on the participant's behalf 2. Patients must be 18 years of age or older 3. Spinal vertebral metastases confirmed by CT, MRI or bone scan. 4. Patients with painful (VAS of at least = 2) vertebral spinal metastases in the thoracic and /or lumbar spine (not cervical). 5. Patients must be willing and able to comply with schedule visits, treatment plan, tests and other study procedures 6. Life expectancy > 6 months. Life expectancy will be evaluated by the study investigator both clinically and by using Linden model. Patient should be in the group B or C of the Linden model. 7. Patients with an ECOG score 0-2 or Karnofsky performance status of = 60% will be eligible for enrolment (see appendix 1). 8. No prior EBRT to the target +/-1 vertebral body level 9. Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes. In addition, females under the age of 55 years must have a serum follicle stimulating hormone, (FSH) level > 40 mIU/mL to confirm menopause 10. Patients of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly (Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard) . 11. Females must not breastfeed during study treatment. 12. Male patients should agree to not donate sperm during study treatment. 13. Absence of any condition hampering compliance with study protocols and follow-up schedule; those conditions should be reviewed with the patient prior to trial registration Exclusion Criteria 1. Patient cannot provide consent 2. Prior radiotherapy to the target +/-1 vertebral body level 3. Life expectancy < 6 months (assessed both clinically and using Linden model) 4. Karnofsky performance status of < 60% 5. Primary bone tumors 6. Plasmacytoma 7. Communicated fracture 8. Associated Impending cord compression or spinal cord compression 9. Epidural involvement |
Country | Name | City | State |
---|---|---|---|
Canada | Cross Cancer Institute | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
AHS Cancer Control Alberta | Cross Cancer Institute |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Improvement in Pain Score based on the Visual Analog Scale | The primary end point is the improvement in pain score of at least 2 points (a decrease of 2 points) on the visual analogue Scale (VAS) without concurrent increase in opioids. | 1,3,6 and 12 months post treatment | |
Primary | Improvement in Pain Score based on the Brief Pain Inventory | The primary end point is the improvement in pain score of at least 2 points (a decrease of 2 points) on the Brief Pain Inventory (BPI) without concurrent increase in opioids. | 1,3,6 and 12 months post treatment | |
Secondary | Changes in back-specific physical functioning | The improvement in back-specific physical functioning is evaluated by the change in Roland-Morris disability questionnaire (RDQ) score. | 1,3,6 and 12 months post treatment | |
Secondary | Incidence of vertebral compression fractures post treatment. | The incidence of vertebral compression fractures will be evaluated by standing lateral spine radiographs of the thoracic and lumbar vertebrae. | Baseline, 6 months and 12 months | |
Secondary | Prospectively quantify pain response using the Visual Analog Scale | Pain response will be assessed by VAS and evaluated using a patient diary based on the International Bone Metastases Working Party Criteria. Based on intake of analgesics, the daily oral morphine equivalent dose (OMED) will be calculated. | 1,3,6 and 12 months post treatment | |
Secondary | Prospectively quantify pain response using the Brief Pain Inventory. | Pain response will be assessed by BPI and evaluated using a patient diary based on the International Bone Metastases Working Party Criteria. Based on intake of analgesics, the daily oral morphine equivalent dose (OMED) will be calculated. | 1,3,6 and 12 months post treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01347307 -
Stereotactic Body Radiotherapy for Spine Tumors
|
N/A | |
Terminated |
NCT00593320 -
Stereotactic Radiosurgery (SRS) for Spine Metastases
|
N/A | |
Recruiting |
NCT05575323 -
Randomized Trial on Same-day SBRT and Surgical Stabilization for Symptomatic Spinal Metastases
|
N/A | |
Completed |
NCT02987153 -
Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study
|
N/A | |
Recruiting |
NCT03363685 -
Verification of Novel Survival Prediction Algorithm for Patients With NSCLC Spinal Metastasis
|
||
Terminated |
NCT02407795 -
Conventional With Stereotactic Radiotherapy for Pain Reduction and Quality of Life in Spinal Metastases
|
N/A | |
Completed |
NCT01365715 -
Preoperative Embolization in Surgical Treatment of Spinal Metastases.
|
N/A | |
Recruiting |
NCT04863612 -
SBRT in the Management of Solid Spinal Metastases
|
||
Recruiting |
NCT01849510 -
Efficacy of Dose Intensified Radiotherapy of Spinal Metastases by Hypofractionated Radiation and IGRT hfSRT Mediated Boost
|
Phase 2 | |
Not yet recruiting |
NCT06244264 -
The Safety and Efficacy of Autologous Transfusion in Spinal Surgery for Lung Cancer With Spinal Metastasis
|
N/A | |
Not yet recruiting |
NCT06220071 -
Multicentric European Study In Patients With Vertebral Metastases
|
||
Completed |
NCT01290562 -
Stereotactic Body Radiotherapy (SBRT) for Spinal/Para-Spinal Metastases (Spine SBRT)
|
Phase 2 | |
Recruiting |
NCT06120426 -
En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor.
|
||
Completed |
NCT03224650 -
Validation of Novel Predictive Score for Patients With Spinal Metastases
|
||
Completed |
NCT02512965 -
Study Comparing Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy (CRT) for Spinal Metastases
|
N/A | |
Not yet recruiting |
NCT06093854 -
Intraoperative Radiotherapy in Treating Spinal Metastases
|
N/A | |
Completed |
NCT02364115 -
Randomized Trial Comparing Conventional Radiotherapy With Stereotactic Radiotherapy in Patients With Bone Metastases - VERTICAL Study
|
N/A | |
Recruiting |
NCT03398915 -
The European Robotic Spinal Instrumentation (EUROSPIN) Study
|
||
Not yet recruiting |
NCT05173467 -
Robot-assisted Invasion-controlled Surgery Versus Traditional-open Surgery Against Metastatic Spinal Tumor
|
N/A | |
Recruiting |
NCT04248543 -
Quantitative MRI for Functional Assessment Following SBRT for Spinal Metastases
|
N/A |